MR prediction of liver fibrosis using a liver-specific contrast agent: Superparamagnetic iron oxide versus Gd-EOB-DTPA. - Wikidata - awgldk - TriplyDB

MR prediction of liver fibrosis using a liver-specific contrast agent: Superparamagnetic iron oxide versus Gd-EOB-DTPA.

MR prediction of liver fibrosis using a liver-specific contrast agent: Superparamagnetic iron oxide versus Gd-EOB-DTPA.

http://www.wikidata.org/entity/Q53164559

about

Liver fibrosis and Gd-EOB-DTPA-enhanced MRI: A histopathologic correlation Quantitative evaluation of the reticuloendothelial system function with dynamic MRI MR Prediction of Liver Function and Pathology Using Gd-EOB-DTPA: Effect of Liver Volume Consideration A comprehensive literatures update of clinical researches of superparamagnetic resonance iron oxide nanoparticles for magnetic resonance imaging.Feasibility of histogram analysis of susceptibility-weighted MRI for staging of liver fibrosis Gd-EOB-DTPA-enhanced MR relaxometry for the detection and staging of liver fibrosis.Gd-EOB-DTPA-enhanced MRI for evaluation of liver function: Comparison between signal-intensity-based indices and T1 relaxometry.Functional remnant liver assessment predicts liver-related morbidity after hepatic resection in patients with hepatocellular carcinoma.Evaluation of gadolinium-EOB-DTPA uptake after portal vein embolization: value of an increased flip angle.A novel serum marker, glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA(+)-M2BP), for assessing liver fibrosis.Performance of gadoxetic acid-enhanced MRI for detecting hepatocellular carcinoma in recipients of living-related-liver-transplantation: comparison with dynamic multidetector row computed tomography and angiography-assisted computed tomography.Increase in left liver lobe function after preoperative right portal vein embolisation assessed with gadolinium-EOB-DTPA MRI.Comparison between T1 relaxation time of Gd-EOB-DTPA-enhanced MRI and liver stiffness measurement of ultrasound elastography in the evaluation of cirrhotic liver.Navigator flip angle optimization for free-breathing T1-weighted hepatobiliary phase imaging with gadoxetic acid.Detection of liver fibrosis using qualitative and quantitative MR elastography compared to liver surface nodularity measurement, gadoxetic acid uptake, and serum markers.Histogram analysis of noncancerous liver parenchyma on gadoxetic acid-enhanced MRI: predictive value for liver function and pathology.Prediction of high-stage liver fibrosis using ADC value on diffusion-weighted imaging and quantitative enhancement ratio at the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI at 1.5 T.T1 ρ Relaxation of the liver: A potential biomarker of liver function.Staging liver fibrosis in chronic hepatitis B with T1 relaxation time index on gadoxetic acid-enhanced MRI: Comparison with aspartate aminotransferase-to-platelet ratio index and FIB-4.Imaging-based evaluation of liver function: comparison of ⁹⁹mTc-mebrofenin hepatobiliary scintigraphy and Gd-EOB-DTPA-enhanced MRI.Stability of liver proton density fat fraction and changes in R 2* measurements induced by administering gadoxetic acid at 3T MRI.[Functional MR imaging of the liver].The diagnostic efficacy of quantitative liver MR imaging with diffusion-weighted, SWI, and hepato-specific contrast-enhanced sequences in staging liver fibrosis--a multiparametric approach.Hepatocellular carcinoma: clinical significance of signal heterogeneity in the hepatobiliary phase of gadoxetic acid-enhanced MR imaging.Diffusion kurtosis imaging and diffusion-weighted imaging in assessment of liver fibrosis stage and necroinflammatory activity.Detecting liver fibrosis with Gd-EOB-DTPA-enhanced MRI: A confirmatory study.Quantitative assessment of hepatic fibrosis in chronic hepatitis B and C: T1 mapping on Gd-EOB-DTPA-enhanced liver magnetic resonance imaging.DWI - histology: a possible means of determining degree of liver fibrosis?Hepatobiliary MRI: Signal intensity based assessment of liver function correlated to 13C-Methacetin breath test.Assessing liver function by liver enhancement during the hepatobiliary phase with Gd-EOB-DTPA-enhanced MRI at 3 Tesla

P2860

Q30359290-0A784D46-40C9-4EB4-A510-CC9D6B8A73A6 Q34000035-036E0B6A-62B3-445C-8C5B-6A4D8B3F95FB Q36279139-182864D8-07EE-49A4-9331-4063E21E8D2B Q36301599-CE73A972-0F38-4504-BDB0-8E815EE647FC Q37114820-05BD7C83-8A89-44B6-B3C9-1B76A697047D Q37609582-50781564-8CCD-42F7-9685-A42B281D7F31 Q37683854-368A13C9-585C-4799-B669-DA5680EBD023 Q38855491-0B97B4E9-6A28-4C0A-A5F5-716019E5E54C Q39373796-56C6C305-3672-40DA-872D-074FB16709DA Q42233241-D9F52E00-4DCF-4380-870F-7C4FC7F6E6A0 Q44043742-27EBD61D-5477-44F5-B1C2-59285A55BE12 Q45801863-4146BB5C-081B-43D6-A916-5BAA1E74E180 Q46171551-A759D486-7A6D-4D68-8461-769C14F26EBA Q46975305-AA6C986D-4102-4B35-80E0-A0FBBE6D1E7F Q47386319-28D05AE4-D5EB-46D4-9E83-275664EFA647 Q50228672-286E8333-17A8-4EAF-8A48-BF8F512063A8 Q50276072-D96DE18E-4FB2-4CAB-8F17-62FC0172CCE0 Q50450574-0515CAA2-66CB-4992-AAD8-717236B0CECB Q51837330-122248F3-1A65-43A6-B0EC-B0B929F9020E Q52871786-AAC0D385-77DF-4A61-A3BB-193BF0AD0320 Q52983887-062F971D-FBBF-4184-8AC7-04FF5D854943 Q52987727-9B4F9593-9749-4E44-A95C-2D329938C35D Q53008408-7AF6724F-B1B3-46A8-9DC1-A1BD9BA46902 Q53058849-7F86DC6E-81BA-4C2E-9763-AA227B4345EC Q54392559-9584C9EB-9E23-4323-9BCA-74B389C3862F Q55003328-D28D515A-3304-42E9-B3D3-2648D2C292FC Q55010500-A2D9E709-F6D1-44F6-AD22-3A8D389FB596 Q55028445-E4DA0342-FF90-4093-A69C-F9C51325CB4E Q55245131-4123054E-5F29-409B-95BF-76437CB212A4 Q58011435-26F2904E-B8DD-466C-8C72-48BC8E8A41CF

P2860

MR prediction of liver fibrosis using a liver-specific contrast agent: Superparamagnetic iron oxide versus Gd-EOB-DTPA.

http://www.wikidata.org/entity/Q53164559

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh-hant

name

MR prediction of liver fibrosi ...... iron oxide versus Gd-EOB-DTPA.

@en

MR prediction of liver fibrosi ...... iron oxide versus Gd-EOB-DTPA.

@nl

type

label

MR prediction of liver fibrosi ...... iron oxide versus Gd-EOB-DTPA.

@en

MR prediction of liver fibrosi ...... iron oxide versus Gd-EOB-DTPA.

@nl

prefLabel

MR prediction of liver fibrosi ...... iron oxide versus Gd-EOB-DTPA.

@en

MR prediction of liver fibrosi ...... iron oxide versus Gd-EOB-DTPA.

@nl

P1433

Q53164559-8271CB28-823A-4014-AA10-EC486C6DC85A

P1476

Q53164559-F19C0439-5C17-4043-AAF4-2823488622CB

P2093

Q53164559-09DD5D13-7FA6-4B0D-9674-E3F597B9E0E0

Q53164559-0F722095-F7F9-4B55-9251-B7495E8648D9

Q53164559-10F353C9-64A9-482C-B7F8-2C0FE949BB9D

Q53164559-2733D092-77FE-475B-826B-C83B209592CC

Q53164559-3B3BA6F1-07EC-4E4D-AB9C-3F0F4BF1FEF6

Q53164559-3CE59FCF-F1C5-43F6-968B-AFB3566BC7AD

Q53164559-4004E03C-3D25-4EEE-9747-8253807EF791

Q53164559-9CC5E3EF-A5A3-463E-8D53-A9F163FB0BA4

Q53164559-A1A1684E-CDCE-4F28-8245-8022F54798DD

Q53164559-C2366D34-4732-4110-B106-089BA974C6E2

P2860

Q53164559-0F330AE4-E07D-45E2-A0A7-58383DFA818B

Q53164559-17FC96FF-615C-48EF-B199-4E5003F2E22E

Q53164559-273CD5BA-DA65-4F75-B7A7-A361DB35D5A1

Q53164559-2BC94FB9-B9C2-434D-8212-81237F6E6312

Q53164559-2E6DEA25-284C-485B-B904-ECC50A01EA06

Q53164559-4C8B91F8-08EB-4758-AD34-B52ED57AFF01

Q53164559-51FF5E1A-20DB-4B11-BEE4-2CEBA4E58DAB

Q53164559-679185B2-D0E8-4F34-BE9A-37C67150C67B

Q53164559-679C2947-6C66-4B7C-B027-37F1579DE889

Q53164559-6A6C7A4C-2364-4D81-8C00-863658271672

P304

Q53164559-7A889E0F-48C1-43F0-B90B-8033B32E12EB

P31

Q53164559-C8C0BE66-B806-4E71-9DC0-4ED860F137B9

P356

Q53164559-F553193C-4D08-4EDF-8A8B-4462C2EF8887

P433

Q53164559-F087217C-97BE-4686-B1DA-A86DF12309DB

P478

Q53164559-813CE90A-2E75-494A-8FD8-C40062294D9A

P577

Q53164559-5AAD61F6-C49A-4AB5-B06D-88696647BF57

P698

Q53164559-B4AA02FA-EBC5-42C1-95B3-07CD490A5F00

P356

P1433

Journal of Magnetic Resonance Imaging

P1476

MR prediction of liver fibrosi ...... iron oxide versus Gd-EOB-DTPA.

@en

P2093

Akihiro Nishie

http://www.w3.org/2001/XMLSchema#string

Akinobu Taketomi

http://www.w3.org/2001/XMLSchema#string

Daisuke Kakihara

http://www.w3.org/2001/XMLSchema#string

Daisuke Okamoto

http://www.w3.org/2001/XMLSchema#string

Hiroshi Honda

http://www.w3.org/2001/XMLSchema#string

Ken Shirabe

http://www.w3.org/2001/XMLSchema#string

Kengo Yoshimitsu

http://www.w3.org/2001/XMLSchema#string

Kousei Ishigami

http://www.w3.org/2001/XMLSchema#string

Makoto Obara

http://www.w3.org/2001/XMLSchema#string

Nobuhiro Fujita

http://www.w3.org/2001/XMLSchema#string

P2860

Assessment of hepatic fibrosis with magnetic resonance elastography.

Evaluation of iron overload.

Evaluation of liver fibrosis: a concise review.

Understanding diagnostic tests 3: Receiver operating characteristic curves.

Advanced liver fibrosis: diagnosis with 3D whole-liver perfusion MR imaging--initial experience.

Genesis of hepatic fibrosis and its biochemical markers.

MR imaging of liver fibrosis: current state of the art.

Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatoce

Hepatobiliary-specific MR contrast agents: role in imaging the liver and biliary tree.

In vitro imaging of human monocytic cellular activity using superparamagnetic iron oxide.

P304

664-671

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JMRI.23691

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

36

http://www.w3.org/2001/XMLSchema#string

P577

2012-04-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22532503

http://www.w3.org/2001/XMLSchema#string